Reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried solid |
| Solubility class | Freely soluble in water | Aqueous buffers also suitable |
| Typical storage temperature | Minus 20 degrees Celsius or colder | Desiccated and light protected |
| Typical analytical method | RP-HPLC with UV detection | 214 nm on C18 column |
| Identity confirmation | Electrospray mass spectrometry | Sequence verified separately |
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
== External links == "Gonadotrophin-Releasing Hormone Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-04. GNRHR+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Betaine transporter (SLC6A12) InterPro: IPR002983 Creatine transporter (SLC6A8) InterPro: IPR002984 Dopamine neurotransmitter transporter (SLC6A3) InterPro: IPR002436 Inebriated neurotransmitter transporter InterPro: IPR002944 GABA neurotransmitter transporter GAT-1 (SLC6A1) InterPro: IPR002980 GABA neurotransmitter transporter GAT-2 (SLC6A13) InterPro: IPR002981 GABA neurotransmitter transporter GAT-3 (SLC6A11) InterPro: IPR002982 Glycine neurotransmitter transporter, type 1 (SLC6A9) InterPro: IPR003028 Noradrenaline neurotransmitter transporter (SLC6A2) InterPro: IPR002435 Orphan neurotransmitter transporter (SLC6A15) InterPro: IPR002438 Serotonin (5-HT) neurotransmitter transporter, N-terminal (SLC6A4) InterPro: IPR013086 Taurine transporter (SLC6A6) InterPro: IPR002434
NADH:ubiquinone reductase (non-electrogenic) (EC 1.6.5.9, NDH-2, ubiquinone reductase, coenzyme Q reductase, dihydronicotinamide adenine dinucleotide-coenzyme Q reductase, DPNH-coenzyme Q reductase, DPNH-ubiquinone reductase, NADH-coenzyme Q oxidoreductase, NADH-coenzyme Q reductase, NADH-CoQ oxidoreductase, NADH-CoQ reductase) is an enzyme with systematic name NADH:ubiquinone oxidoreductase. This enzyme catalyses the following chemical reaction:
For services to Paediatrics and to the Royal College of Paediatrics and Child Health. Graeme David William Odgers, Chairman, Monopolies and Mergers Commission. For services to Industry. Herman George Ouseley, Chairman, Commission for Racial Equality. For services to Community Relations and Local Government. John Michael Pickard, Chairman, London Docklands Development Corporation. For services to Urban Regeneration. Brian Mansel Richards, , Executive Chairman, Peptide Therapeutics Ltd. For services to the Biotechnology Industry. John David Rowland, Chairman, Lloyd's of London. For services to the Insurance Industry. Cyril David Townsend, , Member of Parliament for Bexleyheath. For political service. Professor Guenter Heinz Treitel, , lately Vinerian Professor of English Law, University of Oxford. For services to Law. The Honourable Miles Rawstron Walker, , lately Chief Minister, Isle of Man Government. For services to the Government of the Isle of Man. Ronald Matthew Watson, , Leader, Conservative Group, Association of Metropolitan Authorities. For services to Local Government. William Henry Weston Wells, Regional Chairman, South Thames NHS Executive. For services to Health Care. Raymond William Whitney, , Member of Parliament for Wycombe. For political service. John Basil Zochonis, . For political and public service.
=== Chairmen === R.S. Sharma, 1972 - 1977 A.R. Kulkarni, 1978 - 1981 Niharranjan Ray, 1981 - 1981 Lokesh Chandra, 1982 - 1985 Irfan Habib, 1986 - 1993 Ravinder Kumar, 1993 - 1996 S. Settar, 1996 - 1999 K.S. Sarma (acting), 1999 - 1999 B.R. Grover, 1999 - 2001 K.S. Lal, 2001 - 2001 M.G.S. Narayanan, 2001 - 2003 Kumud Bansal (acting), 2003 - 2004 D.N. Tripathi, 2004 - 2007 K.M. Acharya (acting), 2007 - 2007 Sabyasachi Bhattacharya, 4 March 2007 – 3 March 2010 Sabyasachi Bhattacharya (acting), 4 April 2010 – 20 May 2011 Basudev Chatterjee, 20 May 2011 - 2014 Yellapragada Sudershan Rao, 28 June 2014 - 26 June 2017 A.P Jamkhedkar, 15 February 2018 – 14 January 2022 Raghuvendra Tanwar, 14 January 2022 - present
Sources: en.wikipedia.org
Kashmiri is the most widely spoken language in Jammu and Kashmir, spoken by 53% of the population. Dogri is spoken by 20.5% and Gujari by 9.5% of the total population. Other main languages include Pahari spoken by 7.9%, Hindi by 2.3% and Punjabi by 1.8%. Kashmiri is primarily spoken in the Kashmir Valley and in the upper reaches of the Chenab Valley, with a sizeable number of speakers in Jammu City. Dogri, is spoken throughout the plains areas of Jammu division, as well as in parts of the hills. In Poonch, Rajouri and Ganderbal districts and In the Pir Panjal Range, bordering Pakistan-administered Kashmir, the main language is Gujari spoken by the Gujjars as well as Pahari-Pothwari. In the eastern hills of Jammu division are spoken various Western Pahari languages such as Siraji and Bhaderwahi, which merge with the dialects of western Himachal Pradesh. Urdu is also widely understood and spoken, particularly in the Kashmir region where it acts as the lingua franca alongside Kashmiri and also serves as a medium of instruction along with English, while Hindi is taught and understood in the southern areas of Jammu.
Active transport of carbapenem drugs out of the cell, augmented drug efflux, has been observed in some resistant species. One mechanism of resistance is mutation in or loss of outer membrane porins, preventing antibiotics from entering the cells. Changes within the porin protein gene cause a frameshift, altering the porin structure and function. Changes in the porin protein hinder the diffusion of carbapenem and other antibiotics into the periplasm. Bacteria that express plasmid-borne extended-spectrum β-lactamases (ESBL) can become carbapenem-resistant if an insertion sequence or four-nucleotide duplication is present within chromosomal genes for outer membrane porin proteins. Klebsiella pneumoniae has been associated with the lack of outer membrane porin proteins, OmpK35 and OmpK36. The loss of OmpK36 porins can be attributed to point mutations that result in premature termination of translation, resulting in a truncated and consequently nonfunctional protein. These outer membrane proteins are involved in the transfer of the antimicrobial genetic material in the cell. Loss of either OmpK35 and OmpK36 or only OmpK36 leads to carbapenem resistance. In Klebsiella pneumoniae, the lack of either OmpK35 or OmpK36 leads to carbapenem resistance, but with the lack of both proteins, a high level of resistance is present. An observed 32- to 64-fold increase in minimum inhibitory concentrations occurs for the carbapenems when both proteins are not expressed. CRE produce carbapenemases, a form of β-lactamase.
==== Antigen-independent theories ==== Antigen-independent theories refer to the biochemical properties of HLA-B27. The misfolding hypothesis suggests that slow folding during HLA-B27's tertiary structure folding and association with β2 microglobulin causes the protein to be misfolded, initiating the unfolded protein response (UPR), a pro-inflammatory endoplasmic reticulum (ER) stress response. Although this mechanism has been demonstrated in vitro and in animals, there is little evidence of its occurrence in human spondyloarthritis. The HLA-B27 heavy chain homodimer formation hypothesis suggests that B27 heavy chains tend to dimerise and accumulate in the ER, initiating the UPR. Cell surface B27 heavy chains and dimers can bind to regulatory immune receptors such as members of the killer cell immunoglobulin-like receptor family, promoting the survival and differentiation of pro-inflammatory leukocytes in disease. Another misfolding theory published in 2004 proposes that β2 microglobulin-free heavy chains of HLA-B27 undergo a facile conformational change in which the C-terminal end of domain two, consisting of a long helix, becomes subject to a helix-coil transition involving residues 169–181 of the heavy chain, owing to the conformational freedom newly experienced by domain three of the heavy chain when there is no longer any bound light chain, and owing to the consequent rotation around the backbone dihedral angles of residues 167/168.
=== Art history === In European pre-historic societies, sculptures of female figures with pronounced or highly exaggerated breasts were common. A typical example is the so-called Venus of Willendorf, one of many Paleolithic Venus figurines with ample hips and bosom. Artifacts such as bowls, rock carvings and sacred statues with breasts have been recorded from 15,000 BC up to late antiquity all across Europe, North Africa and the Middle East. Many female deities representing love and fertility were associated with breasts and breast milk. Figures of the Phoenician goddess Astarte were represented as pillars studded with breasts. Isis, an Egyptian goddess who represented, among many other things, ideal motherhood, was often portrayed as suckling pharaohs, thereby confirming their divine status as rulers. Even certain male deities representing regeneration and fertility were occasionally depicted with breast-like appendices, such as the river god Hapy who was considered to be responsible for the annual overflowing of the Nile.
=== Working fluid === sCO2 is chemically stable, reliable, low-cost, non-flammable and readily available, making it a desirable candidate working fluid for transcritical cycles. Supercritical CO2 is used as the working fluid in domestic water heat pumps. Manufactured and widely used, heat pumps are available for domestic and business heating and cooling. While some of the more common domestic water heat pumps remove heat from the space in which they are located, such as a basement or garage, CO2 heat pump water heaters are typically located outside, where they remove heat from the outside air. sCO2 has also been considered as a working fluid for enhanced geothermal systems due to its aqueous and gas properties. sCO2 is also favorable for enhanced geothermal due to its high buoyancy, large expansivity and low viscosity.
Sources: en.wikipedia.org
=== Development === Development of the film was announced on 20 December 2008, although writer Alex Garland had begun working on the script in 2006. British studio DNA Films produced the film, and partnered with sales agency IM Global to sell the worldwide distribution rights. By May 2010, this partnership saw IM Global and its owner Reliance Big Pictures agree to co-finance the 3-D project with a $45 million production budget, and a schedule to begin filming in Johannesburg, South Africa in late 2010. Pete Travis was named as the film's director and Garland, Andrew Macdonald and Allon Reich would produce it. Duncan Jones had previously been offered the role of director. In a 2010 interview, Jones said that his vision for the film was unconventional—describing it as weird, dark, and funny—and it did not mesh well with Garland's script. In September 2010, it was reported that the film would be titled Dredd. Pre-production commenced on 23 August 2010 at Cape Town Film Studios in Cape Town, South Africa. During the 2010 San Diego Comic-Con in July, Urban confirmed that he had been offered the role of Judge Dredd, and on 18 August 2010, it was reported that Urban had the role. In September 2010, it was announced that Thirlby would play Dredd's telepathic rookie Cassandra Anderson. In the same month during the Toronto International Film Festival, the film attracted $30 million in worldwide pre-sales to distributors in 90% of theatrical markets. The sales included a $7 million deal with British distributor Entertainment Film Distributors.
=== 1996–2000 === On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988. In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
== Preparation == CDI can be prepared straightforwardly by the reaction of phosgene with four equivalents of imidazole under anhydrous conditions. Removal of the imidazolium chloride and solvent of the reaction mixture results in the crystalline product in ~90% yield.
=== Pharmacokinetics === Amitriptyline is readily absorbed from the gastrointestinal tract (90–95%). Absorption is gradual with the peak concentration in blood plasma reached after about 4 hours. Extensive metabolism on the first pass through the liver leads to average bioavailability of about 50% (45%-53%). Amitriptyline is metabolized mostly by CYP2C19 into nortriptyline and by CYP2D6 leading to a variety of hydroxylated metabolites, with the principal one among them being (E)-10-hydroxynortriptyline (see metabolism scheme), and to a lesser degree, by CYP3A4. Nortriptyline, the main active metabolite of amitriptyline, is an antidepressant on its own right. Nortriptyline reaches 10% higher level in the blood plasma than the parent drug amitriptyline and 40% greater area under the curve, and its action is an important part of the overall action of amitriptyline. Another active metabolite is (E)-10-hydroxynortriptyline, which is a norepinephrine uptake inhibitor four times weaker than nortriptyline. (E)-10-hydroxynortiptyline blood level is comparable to that of nortriptyline, but its cerebrospinal fluid level, which is a close proxy of the brain concentration of a drug, is twice higher than nortriptyline's. Based on this, (E)-10-hydroxynortriptyline was suggested to significantly contribute to the antidepressant effects of amitriptyline. Blood levels of amitriptyline and nortriptyline and pharmacokinetics of amitriptyline in general, with clearance difference of up to 10-fold, vary widely between individuals.
=== Alternative routes of administration === In rhesus macaques, BCG shows "unprecedented" rates of TB protection when given intravenously. Some risks must be evaluated before it can be translated to humans. The University of Oxford Jenner Institute is conducting a study comparing the efficacy of injected versus inhaled BCG vaccine in already-vaccinated adults.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection at 214 nanometres is the usual approach. Peak area percentage provides a purity figure relative to other components in the sample. Mass spectrometry is then applied to confirm identity.
Aspartate can cyclise into a succinimide intermediate that later hydrolyses back as isoaspartate. Both forms share the same molecular mass, so mass spectrometry alone cannot tell them apart. This shapes how purity data should be interpreted.
Freeze-dried material is normally kept desiccated below minus twenty degrees Celsius and shielded from light. Solutions are prepared shortly before use and held cold. Repeated thawing is avoided because it accelerates aggregation and degradation.
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.